Search

Displaying results 1361 - 1370 of 4233 in total
  1. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    Evinacumab is a recombinant human IgG4 monoclonal antibody targeted against angiopoietin-like protein 3 (ANGPTL3) and the first drug of its kind. The ANGPTL family of proteins serve a number of physiologic functions - including involveme...

  2. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing

  3. Drug

    Elagolix

    go.drugbank.com/drugs/DB11979
    ApprovedInvestigational

    As of 24 July 2018, however, the U.S. … Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women

  4. Drug

    Monobenzone

    go.drugbank.com/drugs/DB00600
    ApprovedWithdrawn

    Monobenzone occurs as a white, almost tasteless crystalline powder, soluble in alcohol and practically insoluble in water.

  5. Drug

    Deutetrabenazine

    go.drugbank.com/drugs/DB12161
    ApprovedInvestigational

    It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets. … Psychomotor symptoms of HD, such as chorea, are related to hyperactive dopaminergic neurotransmission [A14081].

  6. Drug

    Light green SF yellowish

    go.drugbank.com/drugs/DB11183
    Approved

    Light green SF yellowish is also available as sterile strips used as a diagnostic agent when superficial corneal or conjunctival tissue change is suspected. … Light green SF yellowish is a green triarylmethane dye that is used in the preparation of the staining solution which is widely used as a counterstain.

  7. Drug

    Eftrenonacog alfa

    go.drugbank.com/drugs/DB11608
    Approved

    Eftrenonacog alfa acts as a replacement therapy to restore the levels of factor IX and allow normal hemostasis. … Eftrenonacog alfa was developed and marketed as Alprolix for intravenous injection by Biogen. It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016.

  8. Drug

    Capecitabine

    go.drugbank.com/drugs/DB01101
    ApprovedInvestigational

    Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, wh...

  9. Drug

    Axicabtagene ciloleucel

    go.drugbank.com/drugs/DB13915
    ApprovedInvestigational

    The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer.

  10. Drug

    Fondaparinux

    go.drugbank.com/drugs/DB00569
    ApprovedInvestigational

    Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan su...